OakChart

XORTX Therapeutics Inc

XRTXHealthcare·Biotechnology·Canada·Nano·NASD·Nov 11 • 2:12 PM ET

0.8443-0.0057 (-0.67%)
2026-11-11 20:15 CET
Market cap
1.54 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-3.74 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-2.74
P/E
-
Compare

Price

XRTX against its 20, 50 and 200-day averages
2050200earnings
1.002.003.009.3M18.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26XRTXclose 0.8420-day 1.0050-day 1.52200-day 2.050.84

76.6% under the 52-week high of 3.60 on 21 Apr 2026. 52-week low 0.83 on 26 Oct 2026. Last 15 sessions, 38.6% high to low

Profile

XRTX
52-week range, 1% of the way up
0.833.60

XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.

Employees3
IPONov 28, 2018
Beta0.82
ATR, 14d0.14
Rel volume0.03
Short float7.34%
Insider own7.84%
Inst own2.20%

Snapshot

6 groups

Valuation

Index-
Market Cap1.53M
Enterprise Value0.54M
Income-3.74M
Sales0.00M
Book/sh3.18
Cash/sh0.55
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees3
IPONov 28, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.27
P/C1.55
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.59
Current Ratio3.59
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.74
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y51.52% 15.39%
Sales past 3/5Y- -
EPS Y/Y TTM-1.91%
Sales Y/Y TTM-
EPS Q/Q-10.34%
Sales Q/Q-
EarningsAug 17 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own7.84%
Insider Trans0.00%
Inst Own2.20%
Inst Trans1.30%
ROA-83.78%
ROE-99.24%
ROIC-67.93%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-15.80%
SMA50-44.48%
SMA200-58.81%
Trades-

Technical

Shs Outstand1.73M
Shs Float1.67M
Short Float7.34%
Short Ratio0.17
Short Interest0.12M
52W High3.60 -76.55%
52W Low0.83 1.72%
Volatility9.07% 13.40%
ATR (14)0.14
RSI (14)29.73
Beta0.82
Rel Volume0.03
Avg Volume713.17K
Volume16,368

Performance

Perf Week-14.72%
Perf Month-49.74%
Perf Quarter-61.45%
Perf Half Y-63.92%
Perf YTD-69.95%
Perf Year-71.23%
Perf 3Y-93.95%
Perf 5Y-99.37%
Perf 10Y-
Recom1.00
Target Price70.00
Prev Close0.85
Price0.84
Change %-0.67%

Peers

Mkt cap
TickerCompanyMkt cap
UNCYUnicycive Therapeutics Inc104.18M
CALCCalciMedica Inc8.87M
CVKDCadrenal Therapeutics Inc4.89M
PROKProKidney Corp344.70M
TVTXTravere Therapeutics Inc4.98B
DMACDiaMedica Therapeutics Inc526.04M
ICUSeaStar Medical Holding Corp9.99M
ARDXArdelyx Inc779.25M
MLYSMineralys Therapeutics Inc1.42B
VCREVicore Pharma Holding AB ADR318.21M

News

latest 14 of 200
  • XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout (GlobeNewswire) +6.02% -23.78%
  • XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO, Targeting USD$700M+ U.S. Gout Market Opportunity (GlobeNewswire) +15.66%
  • XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO (GlobeNewswire) +10.43%
  • XORTX Re-Engages Investor Relations Program (GlobeNewswire) -5.35%
  • XORTX Announces Termination and Postponement of Investor Relations Program (GlobeNewswire)
  • XORTX Announces Director Resignation (GlobeNewswire)
  • XORTX Appoints New Director (GlobeNewswire)
  • XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO (GlobeNewswire)
  • XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange (GlobeNewswire)
  • XORTX Announces Closing of US$5 Million Public Offering (GlobeNewswire) -10.77%
  • XORTX Announces US$5 Million Public Offering (GlobeNewswire) -14.10%
  • BC-Most Active Stocks (Associated Press) +19.56%
  • XORTX Meets Nasdaq Continued Listing Requirements (GlobeNewswire)
  • XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset (GlobeNewswire) -11.24%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-17-1.050--0.9500.00--
2026Q12026-05-18-0.580--0.5810.00--
2025Q42026-02-26-0.250--0.450---
2025Q32025-11-15-0.650-0.836-0.6690.00-1
2025Q22025-08-14-0.950--0.9470.00--
2025Q12025-05-19-0.950--0.9350.00--
2024Q42025-03-31-0.200-1.4500.2000.00-1
2024Q32024-11-25-1.450--1.0110.00--
2024Q22024-08-140.300-0.2930.00--
2024Q12024-05-20-6.200-2.242-6.2140.00-2
2023Q42024-04-026.900-3.3806.752--2
2023Q32023-11-15-30.150--3.3350.00--
2023Q22023-08-17-4.050-7.786-4.232-0.002
2023Q12023-05-16-4.950-6.552-4.7480.000.002
2022Q42023-03-29-11.376--6.6280.00-2
2022Q32023-02-22-6.224--4.1450.00-2

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-8.451--6.467--
2021FY-6.079-12.440-6.0220.00-
2022FY-23.518-38.898-24.6160.000.00
2023FY-5.450-14.031-5.4450.00-
2024FY-5.750-7.500-5.7550.00-
2025FY-2.800--0.00-
2026FY--1.750--3.25
2027FY-4.000--16.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026FYS2025-11-111003.253.253.25
2026FYS2025-11-101003.253.253.25
2026FYS2025-11-091003.253.253.25
2026FYS2025-11-081003.253.253.25
2026FYS2025-11-071003.253.253.25
2026FYS2025-11-061003.253.253.25
2026FYS2025-11-051003.253.253.25
2026FYS2025-11-041003.253.253.25
2026FYS2025-11-031003.253.253.25
2026FYS2025-11-021003.253.253.25
2026FYS2025-11-011003.253.253.25
2026FYS2025-10-311003.253.253.25
2026FYS2025-10-301003.253.253.25
2026FYS2025-10-291003.253.253.25

Estimate history

EPS, annual-24.896-3.985-6.467-6.022-24.616-5.445-5.755-2.805-2.7444
Period20182019202020212022202320242025TTM
EPS, quarterly0.293-1.0110.2-0.935-0.947-0.669-0.45-0.581-1.045
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.1190.1190.1540.2890.3340.40.6961.3921.731
Period20182019202020212022202320242025MRQ
Shares, quarterly0.5810.5810.6960.7580.7581.0421.3921.3921.731
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.100.110.120.140.060.010.020.010.01
Gross Profit-0.10-0.11-0.12-0.14-0.06-0.01-0.02-0.01-0.01
Selling, General and Administrative Excl. Other3.813.144.005.9110.222.901.030.410.88
Research and Development0.260.570.182.426.770.680.210.030.26
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-3.92-3.26-4.12-6.05-10.28-2.91-1.04-0.43-0.89
Interest Expense-----0.000.010.030.02
Unusual Expense-0.17-0.56-1.04-3.64-2.47-1.34-0.090.002.04
Net Income Before Taxes-3.74-2.66-3.31-2.16-7.29-1.32-0.96-0.47-2.91
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-3.74-2.66-3.31-2.16-7.29-1.32-0.96-0.47-2.91
Net Income From Continuing Operations-3.74-2.66-3.31-2.16-7.29-1.32-0.96-0.47-2.91
Net Income-3.74-2.66-3.31-2.16-7.29-1.32-0.96-0.47-2.91
EPS (Recurring)-2.39-3.22-7.01-11.88-30.45-10.30-6.90-3.98-12.72
EPS (Basic, Before Extraordinaries)-2.74-2.81-5.76-5.44-24.62-6.02-6.47-3.99-24.90
EPS (Diluted)-2.74-2.81-5.76-5.44-24.62-6.02-6.47-3.99-24.90
EBITDA-3.81-3.14-4.00-5.91-10.22-2.90-1.03-0.41-0.88
Non-Operating Income (Expense)0.000.04-0.230.250.530.260.00-0.020.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.020.030.120.120.490.400.220.020.21
Price To Earnings Ratio----5.06----
Shares Outstanding1.731.390.700.400.330.290.150.120.12
Market Capitalization1.541.543.934.6210.5026.639.428.225.78

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.030.030.030.030.030.030.03
Gross Profit-0.02-0.03-0.03-0.03-0.03-0.03-0.03-0.03
Selling, General and Administrative Excl. Other1.670.800.660.690.860.940.640.85
Research and Development0.110.030.050.060.190.280.010.03
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.69-0.82-0.69-0.72-0.89-0.96-0.66-0.87
Interest Expense0.00-------
Unusual Expense0.00-0.01-0.09-0.08-0.15-0.25-0.87-0.24
Net Income Before Taxes-1.69-0.81-0.59-0.65-0.72-0.700.12-0.59
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.69-0.81-0.59-0.65-0.72-0.700.12-0.59
Net Income From Continuing Operations-1.69-0.81-0.59-0.65-0.72-0.700.12-0.59
Net Income-1.69-0.81-0.59-0.65-0.72-0.700.12-0.59
EPS (Recurring)-1.05-0.58-0.50-0.72-1.08-1.17-0.79-1.30
EPS (Basic, Before Extraordinaries)-1.05-0.58-0.45-0.67-0.95-0.930.20-1.01
EPS (Diluted)-1.05-0.58-0.45-0.67-0.95-0.930.20-1.01
EBITDA-1.67-0.80-0.66-0.69-0.86-0.94-0.64-0.85
Non-Operating Income (Expense)-0.000.010.00-0.010.020.02-0.090.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.000.010.000.010.010.010.010.02
Shares Outstanding1.731.391.391.040.760.760.700.58
Market Capitalization1.542.853.914.223.433.643.934.76

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments0.862.473.4510.4314.921.570.610.70
Short Term Receivables0.080.020.060.080.040.050.010.02
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets0.020.190.240.381.010.000.000.00
Total Current Assets0.972.683.7510.8915.971.610.620.72
Net Property, Plant & Equipment0.040.030.020.090.000.000.000.00
Total Investments and Advances1.201.201.201.191.270.000.000.00
Intangible Assets0.190.180.180.200.200.180.210.21
Other Assets0.290.000.320.000.000.000.010.00
Total Assets2.684.095.4712.3617.451.800.840.93
Short Term Debt Incl. Current Port. of LT Debt0.040.040.010.070.000.000.040.00
Accounts Payable0.000.000.000.000.000.000.000.00
Other Current Liabilities0.560.720.281.450.550.810.960.66
Total Current Liabilities0.600.760.291.510.550.811.000.66
Long Term Debt0.000.000.000.010.000.000.000.03
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.533.853.640.000.000.00
Total Liabilities0.600.760.835.384.190.811.000.69
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity2.083.344.646.9913.250.99-0.160.24
Total Shareholders Equity2.083.344.646.9913.250.99-0.160.24
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity2.083.344.646.9913.250.99-0.160.24
Total Liabilities & Stockholders Equity2.684.095.4712.3617.451.800.840.93
Book Value Per Share1.504.7911.6120.9245.906.42-1.371.98
Tangible Book Value Per Share1.364.5311.1720.3245.205.22-3.130.23
Full-Time Employees33332---
Price to Book Ratio0.271.180.761.352.019.55-50.3724.53
Return on Assets-78.38-69.30-24.20-48.88-13.70-72.64-53.75-
Return on Equity-98.00-83.06-37.12-72.01-18.51-232.80-1,315.23-
Return on Invested Capital-127.43-99.30-46.49-104.11-9.95-97.13--1,090.71
Quick Ratio1.613.5312.707.1928.781.990.621.09
Current Ratio1.613.5312.707.1928.781.990.621.09

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-3.71-2.66-3.31-2.16-7.29-1.32-0.96-0.47-2.91
Depreciation0.100.110.120.140.060.010.020.010.01
Other Funds (Non Cash)-0.14-0.56-0.60-3.53-3.48-2.430.130.052.22
Funds from Operations-3.74-3.10-3.80-5.55-10.70-3.74-0.81-0.41-0.68
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.320.340.12-1.031.51-1.100.270.28-0.03
Cash from Operating Activities-5.06-2.77-3.68-6.58-9.19-4.84-0.54-0.14-0.71
Capital Expenditures-0.18-0.06-0.04-0.05-0.05-0.03-0.01-0.01-0.03
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-0.22
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses-0.24-0.240.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.13
Cash from Investing Activities-0.42-0.29-0.04-0.05-0.05-0.03-0.01-0.01-0.12
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.501.522.850.004.9819.510.640.051.47
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock5.501.522.850.004.9819.510.640.051.47
Proceedsfrom Stock Options5.501.522.830.004.9817.500.640.051.47
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.020.000.00-0.300.000.000.00-0.010.00
Other Financing Activities Uses0.020.000.00-0.300.000.000.00-0.010.00
Cash from Financing Activities5.441.432.78-0.364.9419.510.640.041.47
Exchange Rate Effect-0.010.03-0.040.000.670.26---
Net Change in Cash-0.05-1.61-0.97-6.99-3.6314.900.08-0.100.64
Free Cash Flow--2.77-3.68-6.59-9.21-4.84-0.54-0.14-0.71
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments0.990.250.861.191.061.90
Short Term Receivables0.090.060.080.020.010.02
Inventories0.000.000.000.000.000.00
Other Current Assets1.350.060.020.030.100.19
Total Current Assets2.440.370.971.251.172.10
Net Property, Plant & Equipment0.000.010.040.060.080.02
Total Investments and Advances1.201.201.201.201.201.20
Intangible Assets2.550.190.190.190.200.18
Other Assets0.000.370.290.110.090.00
Total Assets6.182.142.682.812.743.50
Short Term Debt Incl. Current Port. of LT Debt0.000.020.040.060.080.02
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities0.680.850.560.780.630.74
Total Current Liabilities0.680.860.600.840.710.76
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.680.860.600.840.710.76
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5.501.282.081.972.032.74
Total Shareholders Equity5.501.282.081.972.032.74
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity5.501.282.081.972.032.74
Total Liabilities & Stockholders Equity6.182.142.682.812.743.50
Book Value Per Share3.180.921.501.892.683.62
Tangible Book Value Per Share1.710.791.361.712.423.38
Full-Time Employees--3---
Price to Book Ratio0.272.221.882.141.691.33
Return on Assets-83.78-98.03-78.38-58.35-49.88-20.80
Return on Equity-99.24-137.44-98.00-94.63-79.44-37.96
Return on Invested Capital-30.71-62.97-28.33-32.91-35.34-25.49
Quick Ratio3.590.431.611.491.652.78
Current Ratio3.590.431.611.491.652.78

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.68-0.81-0.56-0.66-0.74-0.70
Depreciation0.020.030.030.030.030.03
Other Funds (Non Cash)0.02-0.01-0.08-0.07-0.18-0.24
Funds from Operations-1.64-0.79-0.62-0.69-0.89-0.91
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.610.29-0.060.060.070.27
Cash from Operating Activities-3.25-0.50-0.68-0.63-0.82-0.64
Capital Expenditures-0.14-0.00-0.02-0.01-0.02-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.00-0.00-0.240.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.14-0.01-0.26-0.01-0.02-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.15-0.080.640.780.010.09
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.15-0.080.640.780.010.09
Proceedsfrom Stock Options4.15-0.080.640.780.010.09
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.02-0.020.00
Other Financing Activities Uses0.000.000.000.02-0.020.00
Cash from Financing Activities4.14-0.100.620.78-0.040.07
Exchange Rate Effect-0.01-0.000.00-0.010.030.00
Net Change in Cash0.74-0.61-0.310.14-0.86-0.58
Free Cash Flow---0.68-0.63-0.82-0.64

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.34%0.1M1.7M712.44K
2026-10-1514.19%0.2M1.7M705.33K
2026-09-303.68%0.1M1.7M225.26K
2026-09-154.60%0.1M1.7M70.85K
2026-08-310.88%0.0M1.7M13.68K
2026-08-141.13%0.0M1.7M18.75K
2026-07-311.23%0.0M1.7M22.80K
2026-07-151.49%0.0M1.6M1.23M
2026-06-301.62%0.0M1.6M1.24M
2026-06-151.60%0.0M1.6M1.22M
2026-05-291.78%0.0M1.3M1.23M
2026-05-154.29%0.1M1.3M1.23M
2026-04-306.37%0.1M1.3M1.26M
2026-04-153.56%0.0M1.3M58.76K
2026-03-311.55%0.0M0.3M28.75K
2026-03-131.50%0.0M1.3M29.02K
2026-02-272.31%0.0M1.3M28.18K
2026-02-131.72%0.0M1.3M28.57K
2026-01-300.03%0.0M1.3M13.18K
2026-01-151.03%0.0M1.3M394.11K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-08SEC
2026-09-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-18SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-09-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-04SEC
2026-08-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-28SEC
2026-08-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-31SEC
2026-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-29SEC
2026-06-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-15SEC
2026-06-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-12SEC
2026-05-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-19SEC
2026-05-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-05-15424B4SEC
2026-05-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-14SEC
2026-05-13EFFECTEffectiveness filing by commission orderSEC
2026-05-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-08SEC
2026-05-08POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-04-23POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-04-22POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-04-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-21SEC
2026-04-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-13SEC
2026-04-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-01SEC
2026-03-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-26SEC
2026-03-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-26SEC
2026-03-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-26SEC
2026-03-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-25SEC
2026-03-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-24SEC
2026-03-2020-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
CITADEL ADVISORS LLC1.34%
StoneX Group Inc.0.88%
ROYAL BANK OF CANADA0.04%
NATIONAL BANK OF CANADA /FI/0.01%
Clearstead Advisors, LLC0.00%
TD Waterhouse Canada Inc.0.00%

Funds

Fund% owned
-

OakChart. XRTX. Cached 15 minutes.

Some panels did not load: ratings, insider.